Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Sell
22
SURI Quote, Financials, Valuation and Earnings
Last price:
$15.84
Seasonality move
:
20.53%
Day range:
$15.80 - $16.00
52-week range:
$15.37 - $27.52
Dividend yield:
20.73%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.2K
Avg. volume:
3.7K
1-year change:
-23.83%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
$15.87 | -- | -- | -- | $0.68 | 20.73% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$59.70 | -- | -- | -- | $0.00 | 0% | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
$11.98 | -- | -- | -- | $0.00 | 0% | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
$31.38 | -- | -- | -- | $1.17 | 3.74% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$92.97 | -- | -- | -- | $0.08 | 0.37% | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
$42.72 | -- | -- | -- | $0.15 | 1.59% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | 2.143 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.226 | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | 1.903 | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | 1.544 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.543 | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | 0.890 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SURI
Simplify Propel Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
CNCR
Range Cancer Therapeutics ETF
|
-- | -- | -- | -- | -- | -- |
|
SBIO
ALPS Medical Breakthroughs ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
XPH
SPDR S&P Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
Simplify Propel Opportunities ETF vs. Competitors
-
Which has Higher Returns SURI or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About SURI or BBP?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is SURI or BBP More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.647, suggesting its less volatile than the S&P 500 by 35.268%.
-
Which is a Better Dividend Stock SURI or BBP?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 20.73%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or BBP?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns SURI or CNCR?
Range Cancer Therapeutics ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat Range Cancer Therapeutics ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- -
What do Analysts Say About SURI or CNCR?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Range Cancer Therapeutics ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than Range Cancer Therapeutics ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than Range Cancer Therapeutics ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 CNCRRange Cancer Therapeutics ETF0 0 0 -
Is SURI or CNCR More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Range Cancer Therapeutics ETF has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.096%.
-
Which is a Better Dividend Stock SURI or CNCR?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 20.73%. Range Cancer Therapeutics ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. Range Cancer Therapeutics ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or CNCR?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than Range Cancer Therapeutics ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than Range Cancer Therapeutics ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while Range Cancer Therapeutics ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for Range Cancer Therapeutics ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- CNCRRange Cancer Therapeutics ETF-- -- -- --
-
Which has Higher Returns SURI or SBIO?
ALPS Medical Breakthroughs ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat ALPS Medical Breakthroughs ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- -
What do Analysts Say About SURI or SBIO?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ALPS Medical Breakthroughs ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than ALPS Medical Breakthroughs ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than ALPS Medical Breakthroughs ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 SBIOALPS Medical Breakthroughs ETF0 0 0 -
Is SURI or SBIO More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ALPS Medical Breakthroughs ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.65%.
-
Which is a Better Dividend Stock SURI or SBIO?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 20.73%. ALPS Medical Breakthroughs ETF offers a yield of 3.74% to investors and pays a quarterly dividend of $1.17 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. ALPS Medical Breakthroughs ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or SBIO?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than ALPS Medical Breakthroughs ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than ALPS Medical Breakthroughs ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while ALPS Medical Breakthroughs ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for ALPS Medical Breakthroughs ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- SBIOALPS Medical Breakthroughs ETF-- -- -- --
-
Which has Higher Returns SURI or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About SURI or XHS?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is SURI or XHS More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.030, suggesting its more volatile than the S&P 500 by 2.997%.
-
Which is a Better Dividend Stock SURI or XHS?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 20.73%. SPDR S&P Health Care Services ETF offers a yield of 0.37% to investors and pays a quarterly dividend of $0.08 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or XHS?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
-
Which has Higher Returns SURI or XPH?
SPDR S&P Pharmaceuticals ETF has a net margin of -- compared to Simplify Propel Opportunities ETF's net margin of --. Simplify Propel Opportunities ETF's return on equity of -- beat SPDR S&P Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SURISimplify Propel Opportunities ETF-- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- -
What do Analysts Say About SURI or XPH?
Simplify Propel Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Simplify Propel Opportunities ETF has higher upside potential than SPDR S&P Pharmaceuticals ETF, analysts believe Simplify Propel Opportunities ETF is more attractive than SPDR S&P Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings SURISimplify Propel Opportunities ETF0 0 0 XPHSPDR S&P Pharmaceuticals ETF0 0 0 -
Is SURI or XPH More Risky?
Simplify Propel Opportunities ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison SPDR S&P Pharmaceuticals ETF has a beta of 0.757, suggesting its less volatile than the S&P 500 by 24.326%.
-
Which is a Better Dividend Stock SURI or XPH?
Simplify Propel Opportunities ETF has a quarterly dividend of $0.68 per share corresponding to a yield of 20.73%. SPDR S&P Pharmaceuticals ETF offers a yield of 1.59% to investors and pays a quarterly dividend of $0.15 per share. Simplify Propel Opportunities ETF pays -- of its earnings as a dividend. SPDR S&P Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SURI or XPH?
Simplify Propel Opportunities ETF quarterly revenues are --, which are smaller than SPDR S&P Pharmaceuticals ETF quarterly revenues of --. Simplify Propel Opportunities ETF's net income of -- is lower than SPDR S&P Pharmaceuticals ETF's net income of --. Notably, Simplify Propel Opportunities ETF's price-to-earnings ratio is -- while SPDR S&P Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Simplify Propel Opportunities ETF is -- versus -- for SPDR S&P Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SURISimplify Propel Opportunities ETF-- -- -- -- XPHSPDR S&P Pharmaceuticals ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 13
Constellation Energy [CEG] is down 7.45% over the past day.
Sell
1
MCY alert for Jan 13
Mercury General [MCY] is down 6.46% over the past day.
Buy
84
ATZAF alert for Jan 13
Aritzia [ATZAF] is down 6.41% over the past day.
